Posted by Michael Wonder on 26 Dec 2022
BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China
22 December 2022 - BioArctic's partner Eisai announced today that they have initiated submission of data for biologics license application to the NMPA of China for lecanemab, an investigational anti-amyloid beta protofibril antibody.
The registration category of lecanemab was designated as a Category 1 drug (innovative biologics not approved in China or any other countries).
